{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:00:17Z","timestamp":1787032817398,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,15]]},"DOI":"10.7759\/cureus.108875","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:20:34Z","timestamp":1778833234000},"source":"Crossref","is-referenced-by-count":1,"title":["Impact of Once-Daily Ivabradine on Average Resting Heart Rate in Patients With Reduced Ejection Fraction With Systolic Dysfunction: A Multicenter, Post-marketing Observational Study"],"prefix":"10.7759","author":[{"given":"Ajit","family":"Mullasari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jabir","family":"Abdullakutty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Suryavanshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind A","family":"Gadkari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh K","family":"Aggrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avanti","family":"Sable","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin","family":"Sawant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad655.876","article-title":"The global burden of heart failure: a systematic analysis for the Global Burden of Disease Study 2021","volume":"44","author":"Roth GA","year":"2023","unstructured":"Roth GA, Dorsey H, Decleene N, Razo C, Stark B, Johnson C. The global burden of heart failure: a systematic analysis for the Global Burden of Disease Study 2021. Eur Heart J. 2023, 44:10.1093\/eurheartj\/ehad655.876","journal-title":"Eur Heart J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007218","article-title":"The upcoming epidemic of heart failure in South Asia","volume":"13","author":"Martinez-Amezcua P","year":"2020","unstructured":"Martinez-Amezcua P, Haque W, Khera R, et al.. The upcoming epidemic of heart failure in South Asia. Circ Heart Fail. 2020, 13:007218. 10.1161\/CIRCHEARTFAILURE.120.007218","journal-title":"Circ Heart Fail"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese G","year":"2023","unstructured":"Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GM, Coats AJ. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023, 118:3272-87. 10.1093\/cvr\/cvac013","journal-title":"Cardiovasc Res"},{"key":"ref4","unstructured":"The current situation. (2024). Accessed. September 18, 2024: https:\/\/www.iccnhfr.org\/the-current-situation."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.10262","article-title":"Heart failure with reduced ejection fraction: a review","volume":"324","author":"Murphy SP","year":"2020","unstructured":"Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart failure with reduced ejection fraction: a review. JAMA. 2020, 324:488-504. 10.1001\/jama.2020.10262","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2023.11.245","article-title":"Resting heart rate and blood pressure changes in Indian patients with heart failure with reduced ejection fraction: results from a nationwide observational study (Milestone Registry)","volume":"75","author":"Nair T","year":"2023","unstructured":"Nair T, Mohan JC, Roy DG, Jain P, Mahilmaran A, Mahajan V, Kantanavar KA. Resting heart rate and blood pressure changes in Indian patients with heart failure with reduced ejection fraction: results from a nationwide observational study (Milestone Registry). Indian Heart J. 2023, 75:122-3. 10.1016\/j.ihj.2023.11.245","journal-title":"Indian Heart J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244231","article-title":"Heart failure medication after a first hospital admission and risk of heart failure readmission, focus on beta-blockers and renin-angiotensin-aldosterone system medication: A retrospective cohort study in linked databases","volume":"15","author":"Kruik-Koll\u00f6ffel WJ","year":"2020","unstructured":"Kruik-Koll\u00f6ffel WJ, van der Palen J, Doggen CJ, et al.. Heart failure medication after a first hospital admission and risk of heart failure readmission, focus on beta-blockers and renin-angiotensin-aldosterone system medication: A retrospective cohort study in linked databases. PLoS One. 2020, 15:0244231. 10.1371\/journal.pone.0244231","journal-title":"PLoS One"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.18203\/2349-3933.ijam20231872","article-title":"Management of heart failure patients with systolic dysfunction in a real world setting-a physician-based survey","volume":"10","author":"Sawhney JP","year":"2023","unstructured":"Sawhney JP, Jain P, Kantanavar K. Management of heart failure patients with systolic dysfunction in a real world setting-a physician-based survey. Int J Adv Med. 2023, 10:527-37. 10.18203\/2349-3933.ijam20231872","journal-title":"Int J Adv Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh TA","year":"2022","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022, 24:4-131. 10.1002\/ejhf.2333","journal-title":"Eur J Heart Fail"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(18)30306-1","article-title":"Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study","volume":"6","author":"Teng THK","year":"2018","unstructured":"Teng THK, Tromp J, Tay WT, et al.. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. Lancet Glob Health. 2018, 6:1008-18. 10.1016\/S2214-109X(18)30306-1","journal-title":"Lancet Glob Health"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study","volume":"38","author":"Ouwerkerk W","year":"2017","unstructured":"Ouwerkerk W, Voors AA, Anker SD, et al.. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J. 2017, 38:1883-90. 10.1093\/eurheartj\/ehx026","journal-title":"Eur Heart J"},{"key":"ref12","article-title":"Corlanor (ivabradine), first HCN channel blocker, FDA approved for the treatment of patients with heart failure","volume":"9","author":"Fala L","year":"2016","unstructured":"Fala L. Corlanor (ivabradine), first HCN channel blocker, FDA approved for the treatment of patients with heart failure. Am Health Drug Benefits. 2016, 9:56-9.","journal-title":"Am Health Drug Benefits"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-020-00200-8","article-title":"Efficacy and safety of ivabradine once-daily prolonged-release versus twice-daily immediate-release formulation in patients with stable chronic heart failure with systolic dysfunction: a randomized, double-blind, Phase 3 non-inferiority (proficient)","volume":"9","author":"Mullasari A","year":"2020","unstructured":"Mullasari A. Efficacy and safety of ivabradine once-daily prolonged-release versus twice-daily immediate-release formulation in patients with stable chronic heart failure with systolic dysfunction: a randomized, double-blind, Phase 3 non-inferiority (proficient). Cardiol Ther. 2020, 9:505-21. 10.1007\/s40119-020-00200-8","journal-title":"Cardiol Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2020.11.003","article-title":"Resting heart rate as an important predictor of mortality and morbidity in ambulatory patients with heart failure: a systematic review and meta-analysis","volume":"27","author":"Lau K","year":"2021","unstructured":"Lau K, Malik A, Foroutan F, et al.. Resting heart rate as an important predictor of mortality and morbidity in ambulatory patients with heart failure: a systematic review and meta-analysis. J Card Fail. 2021, 27:349-63. 10.1016\/j.cardfail.2020.11.003","journal-title":"J Card Fail"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004112","article-title":"Ivabradine in heart failure: the representativeness of shift (systolic heart failure treatment with the if inhibitor ivabradine trial) in a broad population of patients with chronic heart failure","volume":"10","author":"Das D","year":"2017","unstructured":"Das D, Savarese G, Dahlstr\u00f6m U, Fu M, Howlett J, Ezekowitz JA, Lund LH. Ivabradine in heart failure: the representativeness of shift (systolic heart failure treatment with the if inhibitor ivabradine trial) in a broad population of patients with chronic heart failure. Circ Heart Fail. 2017, 10:004112. 10.1161\/CIRCHEARTFAILURE.117.004112","journal-title":"Circ Heart Fail"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14455","article-title":"Efficacy of ivabradine in heart failure patients with a high-risk profile (analysis from the SHIFT trial)","volume":"10","author":"Abdin A","year":"2023","unstructured":"Abdin A, Komajda M, Borer JS, et al.. Efficacy of ivabradine in heart failure patients with a high-risk profile (analysis from the SHIFT trial). ESC Heart Fail. 2023, 10:2895-902. 10.1002\/ehf2.14455","journal-title":"ESC Heart Fail"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12784","article-title":"Ivabradine: current and future treatment of heart failure","volume":"121","author":"Thorup L","year":"2017","unstructured":"Thorup L, Simonsen U, Grimm D, Hedegaard ER. Ivabradine: current and future treatment of heart failure. Basic Clin Pharmacol Toxicol. 2017, 121:89-97. 10.1111\/bcpt.12784","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg K","year":"2010","unstructured":"Swedberg K, Komajda M, B\u00f6hm M, et al.. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010, 376:875-85. 10.1016\/S0140-6736(10)61198-1","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox K","year":"2008","unstructured":"Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008, 372:807-16. 10.1016\/S0140-6736(08)61170-8","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2011.06.098","article-title":"Effect of carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial)","volume":"151","author":"Volterrani M","year":"2011","unstructured":"Volterrani M, Cice G, Caminiti G, et al.. Effect of carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial). Int J Cardiol. 2011, 151:218-24. 10.1016\/j.ijcard.2011.06.098","journal-title":"Int J Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2174\/1573403X19666230320105623","article-title":"Expert consensus on ivabradine-based therapy for heart rate management in chronic coronary syndrome and heart failure with reduced ejection fraction in India","volume":"19","author":"Mohan JC","year":"2023","unstructured":"Mohan JC, Sathyamurthy I, Panja M, et al.. Expert consensus on ivabradine-based therapy for heart rate management in chronic coronary syndrome and heart failure with reduced ejection fraction in India. Curr Cardiol Rev. 2023, 19:97-106. 10.2174\/1573403X19666230320105623","journal-title":"Curr Cardiol Rev"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-012-0467-8","article-title":"Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study","volume":"102","author":"B\u00f6hm M","year":"2013","unstructured":"B\u00f6hm M, Borer J, Ford I, et al.. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol. 2013, 102:11-22. 10.1007\/s00392-012-0467-8","journal-title":"Clin Res Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61259-7","article-title":"Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial","volume":"376","author":"B\u00f6hm M","year":"2010","unstructured":"B\u00f6hm M, Swedberg K, Komajda M, et al.. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010, 376:886-94. 10.1016\/S0140-6736(10)61259-7","journal-title":"Lancet"},{"key":"ref24","unstructured":"Highlights of prescribing information. (2024). Accessed. September 19, 2024: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/206143orig1s002lbl.pdf."},{"key":"ref25","article-title":"Ivabradine","author":"Reed M","year":"2025","unstructured":"Reed M, Kerndt CC, Nicolas D. Ivabradine. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref26","article-title":"Pharmacokinetic modeling","author":"Bayers JP","year":"2009","unstructured":"Bayers JP, Sarver JG. Pharmacokinetic modeling. Pharmacology Principles and Practice. Elsevier, Amsterdam, Netherlands; 2009. 201-77."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.59497","article-title":"Racial and socioeconomic determinants of cardiovascular health: a comprehensive review","volume":"16","author":"Borkowski P","year":"2024","unstructured":"Borkowski P, Borkowska N, Mangeshkar S, Adal BH, Singh N. Racial and socioeconomic determinants of cardiovascular health: a comprehensive review. Cureus. 2024, 16:59497. 10.7759\/cureus.59497","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/434249-impact-of-once-daily-ivabradine-on-average-resting-heart-rate-in-patients-with-reduced-ejection-fraction-with-systolic-dysfunction-a-multicenter-post-marketing-observational-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:20:38Z","timestamp":1778833238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/434249-impact-of-once-daily-ivabradine-on-average-resting-heart-rate-in-patients-with-reduced-ejection-fraction-with-systolic-dysfunction-a-multicenter-post-marketing-observational-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.108875","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,15]]}}}